Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/57630 
Kompletter Metadatensatz
DublinCore-FeldWertSprache
dc.contributor.authorHerr, Annikaen
dc.contributor.authorSuppliet, Moritzen
dc.date.accessioned2012-04-20-
dc.date.accessioned2012-04-26T14:38:38Z-
dc.date.available2012-04-26T14:38:38Z-
dc.date.issued2012-
dc.identifier.isbn978-3-86304-047-5en
dc.identifier.urihttp://hdl.handle.net/10419/57630-
dc.description.abstractMany countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany follows an innovative approach by differentiating drug co-payments by the drug's price relative to its reference price. In this two-tier system, prescription drugs are completely exempted from co-payments if their prices undercut a certain price level relative to the reference price. We identify the effect of the policy on the prices of all affected prescription drugs and differentiate the analysis by firm types (innovative, generic, branded generic or importing firms). To identify a causal effect, we use a differences-in-differences approach and additionally exploit the fact that the exemption policy had been introduced successively in the different clusters. We use quarterly data from 2007 to 2010 and find empirical evidence for differentiated price setting strategies by firm types, ranging from price decreases of -13.1% (branded generics firms) to increases of +2.0% (innovators) following the introduction of potential reductions in co-payments. We refer to the latter result as the co-payment exemption paradox. Our competition proxy (no. of firms) suggests a significant but small negative correlation with prices.en
dc.language.isoengen
dc.publisher|aHeinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE) |cDüsseldorfen
dc.relation.ispartofseries|aDICE Discussion Paper |x48en
dc.subject.jelD22en
dc.subject.jelD40en
dc.subject.jelI18en
dc.subject.jelI11en
dc.subject.jelL11en
dc.subject.ddc330en
dc.subject.keywordpharmaceuticalsen
dc.subject.keywordpricesen
dc.subject.keywordco-paymentsen
dc.subject.keywordreference pricingen
dc.subject.keywordregulationen
dc.subject.keywordfirm behavioren
dc.titlePharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany-
dc.typeWorking Paperen
dc.identifier.ppn690258666en
dc.rightshttp://www.econstor.eu/dspace/Nutzungsbedingungenen
dc.identifier.repecRePEc:zbw:dicedp:48en

Datei(en):
Datei
Größe
455.38 kB





Publikationen in EconStor sind urheberrechtlich geschützt.